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a  b  s  t  r  a  c  t
Introduction: Patients submitted to hematopoietic stem cell transplantation have an
increased risk of Clostridium difﬁcile infection and multiple risk factors have been identi-
ﬁed.  Published reports have indicated an incidence from 9% to 30% of transplant patients
however to date there is no information about infection in these patients in Chile.
Methods: A retrospective analysis was performed of patients who developed C. difﬁcile infec-
tion  after hematopoietic stem cell transplantations from 2000 to 2013. Statistical analysis
used  the Statistical Package for the Social Sciences software.
Results: Two hundred and ﬁfty patients were studied (mean age: 39 years; range: 17–69),
with 147 (59%) receiving allogeneic transplants and 103 (41%) receiving autologous trans-
plants. One hundred and ninety-two (77%) patients had diarrhea, with 25 (10%) cases of C.
difﬁcile infection being conﬁrmed. Twenty infected patients had undergone allogeneic trans-
plants, of which ten had acute lymphoblastic leukemia, three had acute myeloid leukemia
and  seven had other diseases (myelodysplastic syndrome, chronic myeloid leukemia, severe
aplastic anemia). In the autologous transplant group, ﬁve patients had C. difﬁcile infection;
two had multiple myeloma, one had amyloidosis, one had acute myeloid leukemia and one
had germinal carcinoma. The overall incidence of C. difﬁcile infection was 4% within the ﬁrst
week,  6.4% in the ﬁrst month and 10% in one year, with no difference in overall survival
between infected and non-infected groups (72.0% vs. 67.6%, respectively; p-value = 0.56).
Patients infected after allogeneic transplants had a slower time to neutrophil engraftment
compared to non-infected patients (17.5 vs. 14.9 days, respectively; p-value = 0.008). In the
autologous transplant group there was no signiﬁcant difference in the neutrophil engraft-ment time between infected and non-infected patients (12.5 days vs. 11.8 days, respectively;p-value = 0.71). In the allogeneic transplant group, the median time to acute graft-versus-
host disease was similar between the two groups (p-value = 0.08), as was the incidence of
grades 1–4 acute graft-versus-host disease (40% vs. 48%; p-value >0.05).
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Conclusion: The incidence of C. difﬁcile infection after hematopoietic stem cell transplan-
tation was low, with a signiﬁcant number of cases occurring shortly after transplantation.
Allogeneic transplants had a three-time higher risk of infection compared to autologous
transplants, but this was not associated with increased mortality, decreased overall survival
or  higher risk of acute graft-versus-host disease.
© 2015 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by













































lostridium difﬁcile (CD) is an anaerobic Gram-positive spore-
orming bacillus, responsible for nearly 20% of antibiotic-
ssociated diarrhea in developed countries. The clinical
resentation is varied but may include mild to moderate
iarrhea, toxic megacolon with perforation or death.1 C. dif-
cile infection (CDI) has an impact on length of hospital
tay, costs, morbidity and mortality in adult patients and
hildren,2 and it is a major concern for patients who are
mmunosuppressed, especially after hematopoietic stem cell
ransplantation (HSCT).3–5 The emergence and dissemination
f a high virulent strain (NAP-1/027) has changed the epidemi-
logy of CDI, with high mortality and morbidity as well a high
isk of recurrence, and potential impact on certain patient
ubgroups including HSCT recipients.6–8
The days surrounding HSCT are usually accompanied by
astrointestinal (GI) tract disorders mainly due to mucositis,
ith elevated predisposition to diarrhea and CDI.9 Clinical
anifestations of CDI in this setting may vary from asymp-
omatic colonization to fulminant colitis.10,11 The high risk
f CDI in HSCT patients is due to prolonged hospitaliza-
ion, chemotherapy-related damage of the enteric mucosal
arriers,12 use of broad spectrum antibiotics (prophylac-
ic and therapeutic),13 use of proton-pump inhibitors,14,15
nd in some cases due to infection prior to the HSCT
ospitalization.16
The incidence of CDI in cancer patients receiving
hemotherapy is 3–7%, with approximately 8% developing a
ore severe disease.17 There are data that show the rates
f CDI in HSCT are nine-fold higher than general patients
24.0 vs. 2.6 per 10,000 patients-days, respectively), and 1.4-fold
igher compared with other oncology patients (24.0 vs. 16.8
er 10.000 patients-days, respectively).18 Large epidemiologic
tudies show an overall incidence of CDI of 9.2% at one year
fter transplant.19 In patients submitted to allogeneic HSCT
allo-HSCT), the incidence varies between 15% and 30%,18,20
nd has been associated with the development of acute graft-
ersus-host-disease (aGVHD) of the GI tract and non-relapse
ortality.21
In Chile there are few reports of this infection in hospi-
alized patients, mainly due to lack of surveillance in many
enters, with only one retrospective study showing an overall
ncidence of CDI of 5.3 cases/1000 discharges per year, mainly
n kidney disease patients,22 with no cancer or HSCT recipi-
nt patients included. Since no CDI data in HSCT recipients
s available in Chile, the aim of this study is to describe the
eatures of CDI in HSCT recipients compared to publishedinternational data, in order to improve all the measures to
prevent this complication in a resource-limited setting.
Methods
Patients
A retrospective analysis was performed of all the patients
submitted to HSCT from January 2000 to June 2013 at the
Hospital Clínico Universidad Católica, in Santiago, Chile. This
institution is a 468-bed teaching hospital with a 24-bed hema-
tology unit, and Hematology and Infectious Diseases teams
dedicated to patient care. Data were obtained from the HSCT
database and from electronic and paper patient records.
The data collected included demographics, diagnosis, type
of transplant and conditioning regimen, presence and type
of aGVHD in patients with CDI, time to CDI, antibiotics and
proton-pump inhibitor prescription prior to and during the
HSCT admission. The study was approved by the Ethics Com-
mittee and by the Medical Investigation Center Committee at
the Hospital.
Transplantation  procedure
The patients were divided in two groups, allo-HSCT and
auto-HSCT. The conditioning regimens utilized in allo-HSCT
were myeloablative, including cyclophosphamide and total
body irradiation (TBI), busulfan plus cyclophosphamide, and
reduced intensity conditioning (RIC), including ﬂudarabine
plus cyclophosphamide, ﬂudarabine plus busulfan and busul-
fan plus cyclophosphamide. Patients submitted to auto-HSCT
were conditioned using Melphalan 140 mg/m2, Melphalan
200 mg/m2 and ifosfamide, carboplatin and etoposide (ICE).
All patients were hospitalized in private rooms with a pro-
tective environment (double door rooms with a positive
air pressure system and high efﬁciency particle arresting
ﬁlters). Prophylaxis for standard infectious diseases using
levoﬂoxacin, ﬂuconazole and acyclovir was started on Day
−1 and continued until discharge. Omeprazole was used in
all patients during hospitalization. Filgrastim was started on
Day +5 after transplantation until neutrophil engraftment.
After HSCT, all patients were studied for any sign of infec-
tion (tachycardia, fever, hemodynamic instability), including
at least blood cultures, urine cultures, chest X-ray and stool
samples in cases of diarrhea. If febrile neutropenia was doc-
umented, empiric antibiotic therapy (ceftazidime, amikacin
and vancomycin) was started until the source of infection
was identiﬁed using speciﬁc microbiologic tests. The time to
oter. 2 0 1 5;3  7(6):388–394
Table 1 – Patient characteristics.
Allo-HSCT Auto-HSCT Total
n 147 103 250
Age - years (range) 36 (17–61) 45 (18–69) 39 (17–69)
Gender (male – %) 60% 64% 60%
Conditioning - n (%)
MA 132 (90%) 102 (99%) 234 (94%)
RIC 15 (10%) 1 (1%) 16 (6%)
Main indication for transplant - n (%)
AML 48 (33%) 8 (8%) 56 (22%)
ALL 47 (32%) 1 (1%) 48 (19%)
MM 0 (0%) 36 (35%) 36 (14%)
HL/NHL 6 (4%) 43 (42%) 49 (20%)
Others 43 (29%) 18 (17%) 61 (24%)
Allo-HSCT: allogeneic hematopoietic stem cell transplantation;
Auto-HSCT: autologous hematopoietic stem cell transplantation;
MA: myeloablative; RIC: reduced intensity conditioning; AML:
acute myeloid leukemia; ALL: acute lymphoblastic leukemia; MM:390  rev bras hematol hem
neutrophil engraftment, deﬁned as the ﬁrst of three con-
secutive days of neutrophil count with 0.5 × 109 cells/L was
obtained for all patients as was time to platelet engraftment,
deﬁned as the ﬁrst of ﬁve consecutive days with counts of
20 × 109 cells/L without transfusion support. The presence and
type of aGVHD was diagnosed and graded according to the
Glucksberg criteria and the International Bone Marrow Trans-
plant Registry Database (IBMTR) severity Index.23,24 All aGVHD
was documented for infected patients, if the information was
available, with day of diagnosis and its correlation with CDI.
C.  difﬁcile  infection
The deﬁnition of CDI in HSCT patients was an episode of diar-
rhea with a positive test for C. difﬁcile toxin at any time from the
start of the conditioning regimen until one year after the trans-
plantation (Day −7 until Day +365). Documentation of CDI was
performed using two diagnostic methods available in the insti-
tution: Enzyme Immunoassay (EIA) for C. difﬁcile toxins A and
B from January 2000 to February 2012 and then polymerase
chain reaction (PCR) toxin assay (X-pertTM C. difﬁcile,  GeneX-
pert Technology, Cepheid Company, Sunnyvale, CA, USA) until
the end of the study. Samples were obtained at the bedside
and sent directly to the laboratory for immediate analysis.
The severity of the disease was graded based on the consen-
sus of the Chilean Society of Infectious Disease and Chilean
Society of Gastroenterology. Classiﬁcation included mild to
moderate disease (non-severe CDI), complicated CDI (change
in mental status, megacolon, shock, increased levels of lactic
acid >2.2 mmol/L) and severe CDI (leukocytes >20 × 109 cells/L,
hypoalbuminemia <3 g/dL, creatinine >2.2 mg/dL or increased
more  than 50% of baseline value). Patients with CDI conﬁrmed
by a positive toxin test were put in contact isolation, managed
with hand hygiene using soap and water, avoiding alcohol-
based hand sanitizers and treated with metronidazole (500 mg
q8 PO) or vancomycin (125–250 mg  q6 PO), depending on the
severity of the disease. Antibiotic therapy for CDI was contin-
ued until resolving the diarrheal episode and the neutropenia.
In mild to moderate cases, metronidazole was preferred over
vancomycin as the ﬁrst-line treatment. In cases of intolerance
to metronidazole, oral vancomycin was used as the second
line therapy. In patients with more  symptoms attributable to
infection, but not sufﬁcient to fulﬁll more  severe criteria, or
in cases of recurrent CDI, vancomycin was preferred as ﬁrst-
line treatment. Data for known risk factors was documented
for patients with CDI, including the use of prophylactic and
therapeutic antibiotics in the previous three months, use of
proton-pump inhibitors (omeprazole), use of enteral or par-
enteral nutrition and previous episodes of CDI.
Statistical  analysis
The statistical analysis was performed using the IBM Statisti-
cal Package for the Social Sciences software version 21 (IBM
Company, Armonk, New York, USA). Variables are reported
as numbers and percentages. Survival curves were obtained
using the Kaplan–Meier method and were compared with the
Log-Rank Test, the t test was used for independent samplesmultiple myeloma; HL: Hodgkin’s lymphoma; NHL: non-Hodgkin
lymphoma; CDI: Clostridium difﬁcile infection.
and Fisher exact test for analysis between groups in terms of
CDI and type of transplantation and conditioning.
Results
Patient  characteristics
During the study period, 250 HSCT were performed, includ-
ing 147 allo-HSCT and 103 auto-HSCT. Patient characteristics
are summarized in Table 1. The median age of patients sub-
mitted to allo-HSCT was 36 years (range: 17–61 years) and in
the auto-HSCT group, it was 45 years (range: 18–69). The main
indications for HSCT were acute leukemia (n = 104; 42%), lym-
phoma (n = 49; 20%) and multiple myeloma (n = 36; 14%); 93%
(n = 234) of patients received myeloablative conditioning (MA).
Of the 250 patients studied, diarrhea was seen and docu-
mented in 192 (77%) cases, of which 25 (10%) had CDI, 20 (80%)
in the allo-HSCT group (Table 2). All of the infected patients
had mild to moderate disease, and no deaths were attributable
to this infection. In the CDI group, only three (12%) patients
received vancomycin as ﬁrst-line therapy, with the majority
of the patients (22 patients; 88%) receiving metronidazole,
with a median time to treatment of two weeks (range: 7–24
days). Apart from one patient who received intravenous van-
comycin for the empiric management of febrile neutropenia,
all patients were managed with oral metronidazole or van-
comycin until resolution of the infection. No side effects of
CDI therapy were reported.
Incidence  of  C.  difﬁcile  infection
The overall incidences of CDI in the ﬁrst week, month and
year after transplantation were 4.0%, 6.4% and 10%, respec-
tively, with a median time from HSCT to CDI of 20 days. For
patients submitted to allo-HSCT, the cumulative incidences of
CDI in the ﬁrst week, month and year after the procedure were
5.4%, 8.8% and 13.4%, respectively (median time to infection
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(n  = 103)
Total
(n  = 250)
Total infection 20 (14) 5 (5) 25 (10)
AML 3 (15) 1 (20) 4 (16)
ALL 10 (50) 0 10 (40)
MM – 2 (40) 2 (8)
HL/NHL 0 0 0
CML 4 (20) 0 4 (16)
MDS 1 (5) 0 1 (4)
SAA 2 (10) 0 2 (8)
Others 0 2 (40) 2 (8)
Data presented as n (%).
Allo-HSCT: allogeneic hematopoietic stem cell transplantation;
Auto-HSCT: autologous hematopoietic stem cell transplanta-
tion; AML: acute myeloid leukemia; ALL: acute lymphoblastic
leukemia; MM: multiple myeloma; HL: Hodgkin’s lymphoma; NHL:
non-Hodgkin lymphoma; CML: chronic myeloid leukemia; MDS:
myelodysplastic syndrome; SAA: severe aplastic anemia.
Others included one case of amyloidosis and one case of germinal
cancer.





















Figure 1 – One-year cumulative incidence of Clostridium




















Table 3 – Multivariate analysis of risk factors for
Clostridium difﬁcile infection.
Characteristic HR 95% CI p-Value
Age 1.164 0.354–15.96 0.372
Gender 1.051 0.99–1.10 0.873
Type of transplant 0.775 0.44–28.90 0.951
Disease status at time of
transplantation (CR vs. no
CR)
0.399 0.07–2.57 0.182
Proton-pump inhibitors NS NS NS
Type of conditioning regimen 1.21 0.45–2.36 0.92
Non-infectious diarrhea 0.987 0.01–10.23 0.87tem cell transplantation.
8 days). After auto-HSCT, the cumulative incidences of CDI
n the ﬁrst week, month and year were 1.9%, 2.9% and 4.9%,
espectively (median time to infection 21 days) (Figure 1). Forty
ercent of cases occurred before Day +7 after transplantation,
nd the remaining cases occurred during the follow-up, until
ay +365. Twenty-two patients with CDI took oral metronida-
ole (500 mg  t.i.d.). Three patients received oral vancomycin as
rst-line therapy. Only four patients in the CDI group (16%) had
 second episode of CDI after the transplant (three between
ay +40 and Day +60 and one after Day +200), all of whom
ere successfully treated with oral metronidazole. There were
o differences in incidence of other infections in patients with
nd without CDI.
isk  factors  for  C.  difﬁcile  infection
n the risk factors analysis, all infected patients had
eceived proton-pump inhibitors (omeprazole 20 mg  per day)
nd all received standard infectious disease prophylaxis
levoﬂoxacin, sulfamethoxazole trimethoprim, acyclovir andCR: complete remission; HR: hazard ratio; CI: conﬁdence interval.
ﬂuconazole). Eighty-one percent of the infected patients
(n = 21) used antibiotics other than prophylaxis during the
three months before transplantation, mainly for febrile
neutropenia, and pulmonary, urinary and central venous
catheter-related infections, and other related infections. No
information about antibiotic use before the transplant was
available in the majority of patients without CDI. The antibi-
otics used primarily as treatment of these conditions were
cephalosporins, amikacin, vancomycin and carbapenems.
None of the infected patients received enteral or parenteral
nutrition before the CDI. Patients transplanted for acute
lymphoblastic leukemia (ALL) and acute myeloid leukemia
(AML) represented 40% (10/25) and 16% (4/25) of CDI  cases,
respectively (p-value = 0.041). Multivariate analysis found no
correlation between CDI with the analyzed risk factors, includ-
ing age, gender, disease status at transplantation, type of
transplant, type of conditioning regimen, presence of non-
infectious diarrhea and the use of proton-pump inhibitors
(Table 3).
C.  difﬁcile  infection  and  acute  graft-versus-host  disease
Incidence of grades 1–4 aGVHD was similar between the two
groups; 40% of patients with CDI and 48% of patients with-
out CDI. Grades 3–4 aGVHD was also similar between the two
groups (22%). The median time until this complication was 35
days in infected patients and 30 days in non-infected patients
(p-value = 0.08).
C.  difﬁcile  infection  and  time  to  neutrophil  and  platelet
engraftment
In patients submitted to allo-HSCT, the median time to neu-
trophil engraftment of patients with CDI was longer than in
non-infected patients (17.5 days vs. 14.9 days, respectively;
p-value = 0.008). On the other hand, in patients submitted
to auto-HSCT, the median time to neutrophil engraftment
in patients with CDI versus non-infected patients was 12.5
and 11.8 days, respectively (p-value = 0.71). In terms of time
to platelet engraftment, there were no signiﬁcant differ-
ences between the study groups. The median time to platelet
engraftment was 32.2 days in patients with CDI vs. 25.7 days
in non-infected patients in the allo-HSCT group (p-value = 0.48)
and 31.5 days in patients with CDI vs. 28.1 days in non-infected
patients of the auto-HSCT group (p-value = 0.91) (Table 4).
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Table 4 – Median time to neutrophil and platelet engraftment.
Engraftment Allo-HSCT Auto-HSCT
CDI (+) CDI (−) p-Value CDI (+) CDI (−) p-Value
Neutrophils (days) 17.5 14.9 0.008 12.5 11.8 0.71
Platelets (days) 32.2 25.7 0.48 31.5 28.1 0.91
Allo-HSCT: allogeneic hematopoietic stem cell transplantation; Auto-HSCT: autologous hematopoietic stem cell transplantation; CDI (+): Clostrid-
ium difﬁcile infection; CDI (−): no Clostridium difﬁcile infection.

















Figure 2 – Overall survival at one year in patients submitted
to hematopoietic stem cell transplantation with and
without Clostridium difﬁcile infection.
C.  difﬁcile  infection  and  survival
There was no statistically signiﬁcant difference in overall
survival (OS) between the group with CDI and non-infected
patients at one year after the transplant (72% vs. 67.6%, respec-
tively; p-value = 0.56) (Figure 2).
In the auto-HSCT group, 1-year OS was 77% for patients
with CDI and 60% for patients without CDI (p-value = 0.34). In
the allo-HSCT group, 1-year OS was 75% for patients with CDI
and 61% for patients without CDI (p-value = 0.19).
Discussion
This is the ﬁrst study reporting CDI outcomes in a HSCT popu-
lation in Chile; the overall incidence was similar to previously
published data.16–18 There was a higher incidence of CDI in
patients submitted to allo-HSCT compared to patients sub-
mitted to auto-HSCT, a difference that was seen in other
studies.19,25–27 No correlation was found between CDI and
increased frequency of other infections during the transplan-
tation period, and this study was not able to demonstrate any
correlation between the severity of the CDI and known risk
factors, which may be due to the ubiquity of these traditional
measures in patients submitted to HSCT.28,29
In other studies, some clinical characteristics are associ-
ated with increased risk of CDI, such as the disease status
at transplantation, age, gender or conditioning regimen.28,30However, this study did not demonstrate any correlation
with these characteristics, possibly due to the small sample
size of patients with CDI. All the patients with CDI received
at least two types of antibiotic families (cephalosporins,broad-spectrum penicillin, carbapenems, vancomycin and
quinolones) within the three months before the procedure,
but with no further risk for the development of the disease in
comparison to non-infected patients.
In terms of the transplantation procedure, CDI only
occurred in patients submitted to myeloablative condition-
ing regimens, a ﬁnding that was concordant with studies that
show that these type of regimens are more  toxic, increasing
endothelial damage, affecting the integrity of the intestinal
mucosa31 and increasing immunodeﬁciency.12,17 The use of
TBI is, according to some authors, the main risk factor for the
development of CDI during the ﬁrst week of conditioning.27
However, in this study, the conditioning regimens did not
affect the CDI rate, probably because only 16 out of 240 patients
received RIC (p-value = 0.24).
The peak of CDI in the current study occurred during the
ﬁrst week after transplantation (40% of cases was diagnosed
before Day +7), which could be related to the intestinal tox-
icity peak after TBI. After the initial peak of CDI in the ﬁrst
week after transplant, the cumulative incidence remained sta-
ble over time especially after auto-HSCT. Interestingly it seems
that the incidence of CDI after allo-HSCT continues to increase
almost ten months after transplantation and then stabilizes,
probably due to longer immunosuppression in these patients
secondary to GVHD and delayed immune reconstitution com-
pared to auto-HSCT.
Previous studies have shown that CDI is a risk factor for
the development of GVHD, with a variable incidence of CDI
with aGVHD in different studies, and increased frequency and
severity of episodes and new onset of GI aGVHD associated
with CDI until Day 180 after transplant.19,21,32–34 This study,
however, did not demonstrate this association, with no differ-
ence in terms of aGVHD and CDI, possibly because the number
of infected patients with aGVHD was small.
This study also found that CDI was statistically more  fre-
quent in patients transplanted for ALL compared to AML, a
ﬁnding that could be explained by the fact that the underly-
ing disease requires more  intensive and longer chemotherapy,
prior to the HSCT. Other possible explanations for this ﬁnding
are the greater immunodeﬁciency in ALL patients, higher rates
of antibiotic use for frequent febrile neutropenia episodes,
with more  hospitalizations for complications related to ther-
apy or other unknown factors.
The fact that all cases of CDI were mild to moderate is
probably related to the high index of suspicion, which favors
the early establishment of appropriate therapeutic measures,
thus avoiding the most severe forms of CDI. The good response
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revious evidence that this antibiotic is the best alternative
s ﬁrst-line therapy for mild to moderate CDI.35,36 In this
tudy, only three patients received vancomycin as a ﬁrst-line
herapy, two patients receiving oral vancomycin for GI intol-
rance of metronidazole and one patient due to concomitant
reatment of febrile neutropenia, with a good response in all
ases.
In this patient population, there were no deaths asso-
iated with CDI, a result that is compatible with previous
eports.27 While other studies have found increased mortality
fter CDI in allo-HSCT patients, this has been associated with
he diagnosis of the more  severe forms of the disease.19,34,37
nly four patients (16%) had a second episode of CDI, all
f which occurred after Day +40, were of mild to moderate
everity and responded to metronidazole, suggesting that this
herapy remains efﬁcient even in relapsed cases of CDI.27
he recurrence rate of CDI observed in this population was
ower than that observed in previous reports that described a
ean incidence of recurrence of 20% in patients treated with
etronidazole or vancomycin.38 No speciﬁc reasons for this
ow relapse rate of CDI can be concluded from this study but
ossibly it could be related to factors such as the different diet
nd intestinal ﬂora compared to developed countries, lower
ntibiotic use in the post-transplant setting, less restrictive
iet after transplant, speciﬁc characteristics of the Clostridium
pecies or local practices in the hospital. On the other hand,
DI infection resulted in a statistically signiﬁcant delay in neu-
rophil engraftment in allo-HSCT patients. This observation is
oncordant with the literature that shows that certain infec-
ions can complicate the procedure and cause engraftment
ailure, but until now, the main infectious diseases associ-
ted with engraftment failure are viral infections39 such as
MV,40–42 and human herpes virus 6 (HHV-6).43,44 To date,
here is no available data indicating an association between
ngraftment delay or failure and diarrhea associated with CDI,
specially of mild to moderate severity.
The presence of CDI did not have an impact in OS during
he ﬁrst year after transplant, a ﬁnding that is in agreement
ith other reports found in the literature.27,34 Possible expla-
ations for this ﬁnding include the rapid identiﬁcation of the
nfection due to the high index of suspicion, absence of severe
ases, good sensitivity of C. difﬁcile strains to metronidazole
nd vancomycin, good performance status at the moment of
he infection and other factors that were not elucidated in the
resent study.
The main limitations of this study include its retrospective
ature and the lack of data on some patients especially those
ithout CDI, but despite this, the results compare favorably to
hat has been previously published from developed countries.
onclusions
hese ﬁndings emphasize the importance of measures to pre-
ent CDI, including early suspicion, the appropriate use of
ntibiotics, use of contact precautions and treatment accord-
ng to the severity of the disease. It is important to assess the
ole of the environment and cleaning protocols of the unit, as
he highest incidence of CDI occurs within the ﬁrst week after
ransplantation.
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